UNSPSC 51412503: Azaclorzine hydrochloride

This classification denotes a vasodilating agent with the molecular formula C22H24ClN3OS.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7531I37BK3, chemically known as 10h-phenothiazine, 2-chloro-10-(3-(hexahydropyrrolo(1,2-a)pyrazin-2(1h)-yl)-1-oxopropyl)-, dihydrochloride but more generally known as azaclorzine hydrochloride, which bears US NIH Compound Identifier 39525. Most nations, for tariff and trade purposes, schedule azaclorzine hydrochloride under HS 29343090 and SITC 51578.

As of Q4 2014, AZACLORZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Azaclorzine hydrochloride bears US NLM identifiers UMLS ID C2346890 and NCI Concept Code C72709. SMILES: C1CCC2C(C1)N(C3CC(CCC3S2)CL)C(=O)CCN4CCN5CCCC5C4.CL.CL.

UNSPSC 51412503 Azaclorzine hydrochloride, a Commodity code, represents pharmaceutical products supplied to state and local government health and emergency-services agencies. Recent solicitations under this code show state and local buyers procuring emergency life-support medications, generic multi-source pharmaceuticals for institutional distribution, and direct-to-manufacturer prescription fulfillment programs. The issuing bodies span city fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. Work involves supplying FDA-compliant medications with specified potency, packaging, expiration requirements, and delivery timelines; vendors typically warrant product quality for extended periods and arrange replacement of expired stock before contract expiration.

Activity concentrates in Florida and Minnesota, with a broader multistate footprint through cooperative vehicles. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications—Labetalol, Epinephrine, Adenosine, and Diltiazem formulations for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, featuring a 5 percent Small Local Business Enterprise bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted an RFP in January 2026 for Generic Multi Source Pharmaceuticals and OTC Products across participating state and local facilities including Oregon, with proposals due March 26, 2026 and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription program capabilities as a preliminary market-intelligence phase before formal procurement. Cooperative purchasing vehicles and multistate participation appear standard, with manufacturers expected to maintain relationships with established pharmaceutical wholesalers and comply with cGMP and Drug Supply Chain Security Act certification.